Picture of Hanson Sarah

Sarah Hanson

Co-Chair Lifesciences & Healthcare Sector

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Sarah Hanson is a Partner in the Technology team and is the UK representative for the management committee of the CMS Commercial Group. She works across a number of sectors but has a particular focus on lifesciences and consumer products.  She is Head of the UK Lifesciences Sector Group.

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  During her time with the firm she has been on secondment with Warner Lambert (now part of Pfizer). 

more less

Sarah has also the exclusive winner of the Healthcare and Lifescience category for the UK of the International Law Office (ILO) Client Choice Awards.

Sarah is ranked in Band 2 as a leading practitioner in the Lifesciences – Transactional category in Chambers where sources say she is “rock solid and praise her for her commercial approach” (2016 edition).

"Sarah is ranked as a leading practitioner for licensing work on the basis that she “has forged a strong name in transactions for patent-rich practitioners”."

IAM 1000 top patent practitioners.

Sarah has been recommended in a number of directories including PLC which Lawyer? Lifesciences the PLC Lifesciences Handbook and Legal 500 that described her as “delightful, very responsive and helpful”.

Sarah is ranked as a leading individual in Who’s Who Legal: Lifesciences – Transactional (2016 edition).

Relevant experience

  • Almirall SA on the transfer of its respiratory franchise to AstraZeneca for an initial consideration of USD 875m on completion and up to USD 1.22bn in development, launch and sales related milestone payments.
  • PGT Healthcare LLP in relation to a collaboration with Swisse Wellness Group Party Limited in relation to vitamin, mineral and food supplement products across certain territories.
  • Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.
  • A retail company in relation to a comprehensive IT transformation project with a value of between GBP 1-2bn.  The new IT operating model involves the appointment of a ‘service integrator’ supplier who will manage and integrate all IT services.  The project also involves appointment of multiple IT “service tower” providers.  This includes the following IT services: (i) End User Computing services; (ii) Network services (telecoms networks across company’s entire estate); (iii) Front Office services (front office IT applications including cash and stock management, retail and stock sales, branch accounting); and (iv) Back Office services (back office IT applications including HR, accounting and finance systems).
  • Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell.  We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
  • Camelot in respect of the establishment of the Euro Millions lottery and related matters.
  • On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
  • Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
  • hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
more less


2004 – Intellectual Property Diploma, Bristol University, Bristol

1994 – Distinction, The College of Law, LPC, Chester

1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge

more less




Biotech Industry Association

Society for Computers & Law


more less


European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry

more less

Lectures list

EU Pharma Law Conference – May 2015

more less


Show only
11 January 2017
Food and beverage
EU Medical Devices Regulation and In-Vitro Medical Devices Regula...
The EU Medical Devices Regulation and In-Vitro Medical Devices Regulation (the “Regulations”) were adopted on 5 April 2017, following a final vote at the European Parliament. The Regulations were proposed by the Commission in 2012 (as discussed in our previous.
Our ehealth capabilities
EMA & HMA establish task force to explore big data's potential fo...
A new task force has been set up to explore how medicines regulators in the EU can use big data to improve human and animal health. The task force has been established by the European Medicines Agency (“EMA”), in conjunction with the EEA Heads of Medicines.
CMS Global Lifesciences Forum 2015
Shaping the future through innovation and collabor...
CMS Global Lifesciences Forum Report 2015
The Antidote - Winter 2015
Connect: CMS Alumni Annual Review 2014
Supporting your business
The Antidote - Spring 2014
Taking a look at "pharmerging" markets and the res...
CMS retail sector
Health and beauty
The Antidote - Predictions for the Lifesciences se...
CMS advises on one of the largest multi-jurisdicti...
What people say about us
Medical Devices